Episode 5: Tony Losasso – The Next Claritin? GLP-1 Drugs and the Future of Obesity Treatment
On Background - A Healthcare PodcastShow Notes
In this episode, Tony Losasso, a professor of economics and Driehaus Fellow at Depaul University, discusses his experiences in public service, particularly his role in the Center for Program Integrity at CMS during the implementation of the Affordable Care Act. He shares insights on the challenges of government work, the importance of translating academic research into public understanding, and the role of pharmaceuticals in addressing obesity from his recent Wall Street Journal op-ed.
More from On Background - A Healthcare Podcast
In this episode, hosts Stephen Parente and Thom Gunderson explore the complexities of the 340B drug pricing program, its origins, current challenges, and potential reforms. Guest expert Sayeh Nikpay from the University of Minnesota provides insights into how the program operates, its unintended consequences, and policy options for better transparency and effectiveness.
In this episode of On Background, host Stephen Parente conducts a roundtable with previous guests Marta Wosinska, Rena Conti, and Doug Holtz-Eakin on the current challenges, innovations, and future prospects in the healthcare marketplace, including drug pricing, insurance markets, and technological advancements like AI.
In this episode of On Background, we talk with Kenny White and explore the complexities of the US health insurance industry, the role of managed care, AI's potential in healthcare, and future policy directions, delving into cost management, risk analysis, and the sustainability of current models.
In this year-end review, hosts Stephen Parente, Thom Gunderson, and Matt Stoll discuss key topics covered throughout 2025 in the On Background podcast: the impact of AI, investment trends, market uncertainties, and the future of MedTech. They explore the challenges and opportunities presented by AI in healthcare, the need for clear direction in investment, and the importance of innovation in drug development. The conversation also touches on healthcare costs, consumer engagement, and the regulatory landscape, setting the stage for future discussions in the coming year.